Literature DB >> 8025978

Time course of nitric oxide production and epithelial dysfunction during ischemia/reperfusion of the feline small intestine.

S Kanwar1, B L Tepperman, D Payne, L R Sutherland, P Kubes.   

Abstract

The objective of this study was to correlate nitric oxide production with time of reperfusion of the post-ischemic feline small intestine. Epithelial permeability, quantitated as blood-to-lumen clearance of 51Cr-EDTA, following 1 hr of ischemia and 4 hr of reperfusion of the small intestine, increased approximately 10-fold. This increase was further augmented by L-NAME infusion between 60 and 120 min but not at 240 min. Ca(2+)-dependent nitric oxide synthase activity was reduced by approximately 50% at 3 and 4 hr of reperfusion, whereas Ca(2+)-independent nitric oxide synthase activity was undetectable throughout the experiment. Administration of L-arginine at the start of reperfusion attenuated the reperfusion-induced epithelial barrier dysfunction for the first 120 min but not at 180 or 240 min. Continuous infusion of a nitric oxide donor (CAS 754) following 1 hr of reperfusion reduced epithelial permeability at 4 hr of reperfusion. In conclusion, a reduction in nitric oxide production was observed with time of reperfusion, possibly due to reduced nitric oxide synthase levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025978

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  11 in total

1.  Bradykinin B2 receptor antagonist FR173657 ameliorates small bowel ischemia-reperfusion injury in dogs.

Authors:  Kazuhisa Arakawa; Izumi Takeyoshi; Yoshihiko Akao; Osamu Totsuka; Koshi Matsumoto; Yasuo Morishita
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

2.  Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion.

Authors:  S Cuzzocrea; E Mazzon; L Dugo; A P Caputi; K Aston; D P Riley; D Salvemini
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Fructose-1,6-biphosphate in rat intestinal preconditioning: involvement of nitric oxide.

Authors:  A Sola; J Roselló-Catafau; E Gelpí; G Hotter
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Nitric oxide decreases the permselectivity of the paracellular pathway in thick ascending limbs.

Authors:  Casandra M Monzon; Jeffrey L Garvin
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

5.  Detection and comparison of nitric oxide in clinically normal horses and those with naturally acquired small intestinal strangulation obstruction.

Authors:  M H Mirza; J L Oliver; T L Seahorn; G Hosgood; R M Moore
Journal:  Can J Vet Res       Date:  1999-10       Impact factor: 1.310

Review 6.  Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention.

Authors:  Diana L Diesen; Paul C Kuo
Journal:  J Surg Res       Date:  2009-10-27       Impact factor: 2.192

7.  Prophylactic administration of L-arginine improves the intestinal barrier function after mesenteric ischaemia.

Authors:  R Schleiffer; F Raul
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

Review 8.  Animal models of ischemia-reperfusion-induced intestinal injury: progress and promise for translational research.

Authors:  Liara M Gonzalez; Adam J Moeser; Anthony T Blikslager
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-11-20       Impact factor: 4.052

9.  Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion.

Authors:  Emanuela Masini; Salvatore Cuzzocrea; Emanuela Mazzon; Carmelo Muià; Alfredo Vannacci; Francesca Fabrizi; Daniele Bani
Journal:  Br J Pharmacol       Date:  2006-07-17       Impact factor: 8.739

10.  Tyrphostin AG 126 reduces intestinal ischemia-reperfusion injury in the rat.

Authors:  Stefania Marzocco; Emanuela Mazzon; Aldo Pinto; Giuseppina Autore; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.